CMC Development – Downloads

 

About Bachem

Innovation for TIDES

CMC Development

NCE Peptides

Oligo Therapeutics

Tag-Assisted Peptide Synthesis (TAPS)

White Papers and Case Studies

Continuous chromatography white paper cover

IMPROVING OLIGO MANUFACTURE WITH STIRRED-BED

Oligonucleotide-based active pharmaceutical ingredients (APIs) have emerged as a powerful approach to treating diseases. With hundreds of them in advanced clinical trials, a potential metric ton demand for certain products is expected that might not be easily fulfilled by conventional solid phase oligonucleotide synthesis (SPOS). It is essential to develop more efficient, more sustainable, and highly scalable manufacturing techniques.
This whitepaper explains how the innovative stirred-bed technology (SBT) for SPOS fulfills all these requirements and represents an economical engineering solution with a simple reactor design and adapted chemistry. Thus, ton-scale commercial oligonucleotide API manufacture with unmatched process mass intensity is within reach.

Download Case Study

By completing this form, the requested document will be sent directly to your email.

Continuous chromatography white paper cover

Continuous Chromatography – Pushing the boundaries of peptide and oligonucleotide production

During the manufacturing of a peptide API, well-established purification is crucial for achieving high purity and yield, and at the same time is a major determinant for the cost efficiency and process productivity.

Multicolumn Countercurrent Solvent Gradient Purification (MCSGP) has shown to achieve substantially higher capacity and yield than single-column batch processes. This innovative purification process leads to time savings, economic advantages and a lower environmental footprint.

Download White Paper

By completing this form, the requested document will be sent directly to your email.

MCSGP Case Study for Oligonucleotides

Greener purification at large-scale

An oligonucleotide case study

Resembling a new era of innovative drug development, the interest of the biopharma industry in the oligonucleotide markets has grown significantly in the past five years.

In 2021, the US Food and Drug Administration (FDA) approved the first-in-class siRNA to lower cholesterol – a drug with a multi-ton potential to treat millions of patients per year. Moving forward, the demand for oligonucleotide batch size is likely to increase as well as the need for large-scale manufacturing capacity to support this growth.

Download Case study

By completing this form, the requested document will be sent directly to your email.

Stay Informed

Our Newsletter is the ideal method to remain up to date on Bachem’s latest industry news and insights.
Whether you’re a current customer or just curious about what we have to offer, our newsletter is a wonderful way to stay in touch.

Subscribe to our general newsletter

"*" indicates required fields

Name*
Country
This field is hidden when viewing the form
Submission Time
: